McDonnell Boehnen Hulbert & Berghoff LLP partner Kevin E. Noonan, Ph.D., co-authored an article entitled, “Gene Patents and Personalized Cancer Care: Impact of the Myriad Case on Clinical Oncology” that appears in the July 20, 2013 edition of Journal of Clinical Oncology. Genomic discoveries have transformed the practice of oncology and cancer prevention. Diagnostic and therapeutic advances based on cancer genomics developed during a time when it was possible to patent genes. A case before the Supreme Court, Association for Molecular Pathology v Myriad Genetics, Inc seeks to overturn patents on isolated genes. Although the outcomes are uncertain, it is suggested here that the Supreme Court decision will have few immediate effects on oncology practice or research but may have more significant long-term impact. View the article